title: Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries.
abstract: The renoprotection of erythropoietin (EPO) and its derivatives such as helix B surface peptide (HBSP) have attracted a great deal of attention from scientists and clinicians alike. The evolutional achievement in the dissociation of tissue protection and erythropoiesis is obtained through HBSP characterisation and synthesis. We performed a series of studies using EPO, as well as HBSP, in a variety of biological models subjected to transplant-related renal injuries such as ischemia reperfusion injury (IRI) and/or immunosuppressant nephrotoxicity. In this short review, we would like to address the effects of EPO in different formats, and its underlying mechanisms with focuses on apoptosis and inflammation in in vitro, ex vivo and in vivo renal injury models, and to further explore potential applications and challenges in humans.
authors.affiliation: Renal Group, Basic Medical Research Centre, Medical College of Nantong University, Nantong, Jiangsu. China.
authors.forename: Yufang
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, Jiangsu. China.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Pathology, Medical College of Nantong University, Nantong, Jiangsu. China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Renal Group, Department of Infection, Immunity and Inflammation, Maruice Shock Medical Sciences Building, University Road, Leicester LE1 7RH. United Kingdom.
authors.forename: Bin
authors.initials: B
authors.lastname: Yang
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D053648:Cytokine Receptor Common beta Subunit / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000494:pharmacology*; D005786:Gene Expression Regulation; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology*; D020011:Protective Agents / Q000494:pharmacology*; D017467:Receptors, Erythropoietin / Q000235:genetics / Q000378:metabolism; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D053648:Cytokine Receptor Common beta Subunit; C554270:EPO protein, human; D010446:Peptide Fragments; D020011:Protective Agents; D017467:Receptors, Erythropoietin; C585201:glutaminyl-glutamyl-glutaminyl-leucyl-glutamyl-arginyl-alanyl-leucyl-asparagyl-seryl-serine; D004921:Erythropoietin
keywords: Erythropoietin; apoptosis and oxidation; helix B surface peptide; inflammation; ischemia reperfusion injury